Metsera (NASDAQ:MTSR) Now Covered by Analysts at Wells Fargo & Company

Wells Fargo & Company initiated coverage on shares of Metsera (NASDAQ:MTSR) in a research note published on Friday morning, Marketbeat reports. The brokerage issued an overweight rating and a $65.00 price objective on the stock.

A number of other analysts have also issued reports on MTSR. Cantor Fitzgerald began coverage on Metsera in a research note on Tuesday, February 25th. They issued an “overweight” rating on the stock. Guggenheim increased their price target on shares of Metsera from $56.00 to $62.00 and gave the stock a “buy” rating in a research note on Tuesday, June 10th. Evercore ISI started coverage on Metsera in a report on Tuesday, February 25th. They set an “outperform” rating for the company. Finally, Bank of America began coverage on Metsera in a report on Tuesday, February 25th. They issued a “buy” rating and a $38.00 target price on the stock. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Metsera has an average rating of “Buy” and an average target price of $55.00.

Metsera Trading Up 6.8%

Shares of NASDAQ MTSR opened at $29.60 on Friday. Metsera has a 1 year low of $12.30 and a 1 year high of $37.99. The stock’s 50 day moving average price is $25.70.

Metsera (NASDAQ:MTSR) last issued its quarterly earnings results on Monday, May 12th. The company reported ($1.03) earnings per share for the quarter.

Institutional Investors Weigh In On Metsera

Large investors have recently made changes to their positions in the business. Bank of New York Mellon Corp acquired a new stake in Metsera in the 1st quarter valued at $884,000. New York State Common Retirement Fund acquired a new stake in Metsera in the first quarter valued at approximately $131,000. Alphabet Inc. acquired a new position in shares of Metsera during the first quarter worth $135,059,000. Massachusetts Financial Services Co. MA purchased a new position in shares of Metsera in the first quarter valued at $13,111,000. Finally, Jennison Associates LLC acquired a new stake in Metsera during the 1st quarter valued at $9,679,000.

About Metsera

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.